Production (Stage)
D
Pharvaris N.V. PHVS
$16.05 -$0.57-3.43% NASDAQ
Recommendation
Prev Close
$16.62
Volume
81,019
Avg Vol (90D)
60,895
Market Cap
$905.68M
Dividend & Yield
--
52-Week Range
$11.51 - $25.50
P/E (TTM)
--
EPS (TTM)
-$3.02
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Pharvaris (PHVS) Receives Continued "Outperform" Rating from Wedbush PHVS Stock News
6/5/2025 - GuruFocus
Wedbush Reaffirms "Outperform" Rating for Pharvaris (NASDAQ:PHVS)
6/5/2025 - MarketBeat
Oppenheimer Remains a Buy on Pharvaris (PHVS)
6/5/2025 - TipRanks Financial Blog
Citizens JMP Sticks to Their Buy Rating for Pharvaris (PHVS)
6/5/2025 - TipRanks Financial Blog
Pharvaris (PHVS, $16.62) entered Downtrend as Momentum indicator drops below 0 level on Jun 04, 2025
6/5/2025 - Tickeron - Stocks
Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?
6/3/2025 - MarketBeat
Pharvaris (PHVS, $16.49) entered Downtrend as Momentum indicator drops below 0 level on Jun 02, 2025
6/3/2025 - Tickeron - Stocks
Pharvaris (PHVS) Spotlights Promising Deucrictibant Data at Key Workshop PHVS Stock News
6/2/2025 - GuruFocus
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in ...
6/2/2025 - GuruFocus
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in ...
6/2/2025 - GuruFocus
Pharvaris presents data supporting ongoing clinical development of deucrictibant
6/2/2025 - The Fly
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
6/2/2025 - Globe Newswire
Pharvaris (NASDAQ:PHVS) Shares Up 6.7% - Time to Buy?
5/30/2025 - MarketBeat
Pharvaris (PHVS, $16.72) price moved above its 50-day Moving Average on May 29, 2025
5/30/2025 - Tickeron - Technical Analysis
Pharvaris (PHVS, $16.72) Stochastic Oscillator left the oversold zone on May 29, 2025
5/30/2025 - Tickeron - Technical Analysis
Pharvaris (PHVS) Gets a Buy from Morgan Stanley
5/27/2025 - TipRanks Financial Blog
VR Adviser LLC Has $61.73 Million Stock Holdings in Pharvaris (NASDAQ:PHVS)
5/22/2025 - MarketBeat
Pharvaris (PHVS, $16.4) entered Downtrend as Momentum indicator drops below 0 level on May 21, 2025
5/22/2025 - Tickeron - Stocks
Soleus Capital Management L.P. Grows Holdings in Pharvaris (NASDAQ:PHVS)
5/21/2025 - MarketBeat
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming ...
5/19/2025 - GuruFocus
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming ...
5/19/2025 - GuruFocus
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
5/19/2025 - Globe Newswire
Sphera Funds Management LTD. Reduces Stake in Pharvaris (NASDAQ:PHVS)
5/16/2025 - Ticker Report
Pharvaris (PHVS) Target Price Revised by Cantor Fitzgerald PHVS Stock News
5/14/2025 - GuruFocus
Pharvaris (PHVS) Target Price Increased by Wedbush Amid Clinical Progress PHVS Stock News
5/14/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$171.01M
EBIT (TTM)
-$171.14M
Net Income (TTM)
-$163.68M
Balance Sheet
Total Assets (Q)
$268.12M
Total Debt (Q)
$800.90K
Total Liabilities (Q)
$24.56M
Book Value Per Share (Q)
$4.47
Cash Flow
Cash from Operations (TTM)
-$144.11M
Cash from Investing (TTM)
-$720.90K
Cash from Financing (TTM)
$1.96M
Net Change in Cash (TTM)
-$141.48M
Filings
Filing Date
Tuesday, May 13, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
0.58
7-Day Total Return
1.33%
30-Day Total Return
8.30%
60-Day Total Return
0.00%
90-Day Total Return
-10.93%
Year to Date Total Return
-13.43%
1-Year Total Return
-2.73%
2-Year Total Return
85.55%
3-Year Total Return
-13.24%
5-Year Total Return
--
52-week Low
Apr 10, 2025 - $11.51
52-week High
Nov 04, 2024 - $25.50
Valuation
Market Cap
$905.68M - Small Cap
Enterprise Value
$650.86M
Price/Sales (TTM)
--
Price/Book (Q)
3.72
Dividends and Shares
Shares Outstanding
54.49M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
pharvaris.com
Phone Number
31 712036410
Address
Grafenauweg 8
Zug, 6300
Country
Switzerland
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other... more
NASDAQ 06/05/2025 4:00PM Eastern Quotes delayed